CIBRA Capital Ltd Purchases Shares of 37,543 SpringWorks Therapeutics (NASDAQ:SWTX)

CIBRA Capital Ltd purchased a new position in SpringWorks Therapeutics (NASDAQ:SWTX - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 37,543 shares of the company's stock, valued at approximately $1,657,000. SpringWorks Therapeutics accounts for about 0.6% of CIBRA Capital Ltd's portfolio, making the stock its 18th largest position. CIBRA Capital Ltd owned 0.05% of SpringWorks Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Allspring Global Investments Holdings LLC purchased a new position in shares of SpringWorks Therapeutics in the first quarter valued at about $208,000. AMI Asset Management Corp increased its holdings in shares of SpringWorks Therapeutics by 27.3% in the first quarter. AMI Asset Management Corp now owns 50,640 shares of the company's stock worth $2,235,000 after purchasing an additional 10,849 shares during the last quarter. Oppenheimer Asset Management Inc. increased its stake in SpringWorks Therapeutics by 7.7% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 13,526 shares of the company's stock worth $597,000 after acquiring an additional 967 shares during the last quarter. FNY Investment Advisers LLC purchased a new position in shares of SpringWorks Therapeutics in the 1st quarter worth $466,000. Finally, Bayshore Asset Management LLC bought a new stake in shares of SpringWorks Therapeutics in the 1st quarter valued at approximately $214,000.

Analysts Set New Price Targets

SWTX has been the subject of several analyst reports. Guggenheim reissued a "neutral" rating and issued a $47.00 price objective on shares of SpringWorks Therapeutics in a research note on Monday, May 12th. HC Wainwright restated a "neutral" rating and set a $47.00 price target (down previously from $74.00) on shares of SpringWorks Therapeutics in a research note on Wednesday, April 30th. TD Cowen reiterated a "hold" rating and issued a $47.00 price target (down previously from $66.00) on shares of SpringWorks Therapeutics in a report on Tuesday, April 29th. Barclays restated an "equal weight" rating and issued a $47.00 target price (down previously from $63.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Finally, Evercore ISI cut SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th. Seven analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $52.57.

SpringWorks Therapeutics Stock Performance

NASDAQ SWTX remained flat at $46.99 on Wednesday. The firm has a fifty day simple moving average of $46.38 and a 200 day simple moving average of $44.30. The company has a market cap of $3.54 billion, a price-to-earnings ratio of -13.78 and a beta of 0.70. SpringWorks Therapeutics has a twelve month low of $28.21 and a twelve month high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative return on equity of 51.10% and a negative net margin of 115.60%. The firm had revenue of $49.09 million for the quarter, compared to analyst estimates of $64.19 million. On average, research analysts anticipate that SpringWorks Therapeutics will post -2.05 earnings per share for the current year.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.